Radiopharm Theranostics Limited (RADX)

2.41 +6.64% (+0.15)

Over 1M: -23.5%

2026-08-28
Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

2 2.5 3
31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug 26 Aug

Financials Annual

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
FY23 — Revenue: 292.4K FY23 — Operating Cash Flow: -23.2M FY23 — Free Cash Flow: -23.2M FY23 — Net Income: -34.6M FY24 — Revenue: 299.2K FY24 — Operating Cash Flow: -23M FY24 — Net Income: -47.9M FY25 — Revenue: 3.6M FY25 — Operating Cash Flow: -36.6M FY25 — Net Income: -38.3M -45M -30M -15M 0 15M
FY23 FY24 FY25
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-06-30, reported in USD. The newest fact in the filings is dated 2025-06-30, 426 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 52.2%
OE margin -1060.7%
Oper. margin -1050.6%
ROIC -219.2%
Accruals -2.0%
Asset turnover 0.042×
EBITDA margin -979.2%
FCF margin -1008.6%
OCF margin -1008.6%
Profit margin -1055.3%
ROA -44.3%
ROCE -53.4%
ROE -89.4%
Capex / sales —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.0
ND/EBITDA —
Interest cover -584.6×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 2.7×
Cash runway 0.79 yr
F-score 4.5 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +125.2%
Shares change +439.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.